Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A trial comparing NNC0148-0287 C (insulin 287) versus insulin glargine U100, both in combination with metformin, with or without DPP4 inhibitors and with or without SGLT2 inhibitors, in basal insulin treated subjects with type 2 diabetes mellitus

Trial Profile

A trial comparing NNC0148-0287 C (insulin 287) versus insulin glargine U100, both in combination with metformin, with or without DPP4 inhibitors and with or without SGLT2 inhibitors, in basal insulin treated subjects with type 2 diabetes mellitus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin icodec (Primary) ; Dipeptidyl peptidase 4 inhibitors; Insulin glargine; Metformin; Sodium-glucose transporter 2 inhibitors
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LAI287
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 29 Jun 2021 Results from NCT03951805 and NCT03922750; comapring CGM-derived hypoglycemic episode duration between icodec and IGlar U100 in insulin-naive and insulin-experienced patients with Type-2-diabetes-mellitus, presented at the 81st Annual Scientific Sessions of the American Diabetes Association
    • 29 Jun 2021 Results of a post hoc analysis comparing the time in range, time above range and and below range for icodec (LD and no loading dose - NLD) vs IGlar U100 throughout the 16-week period presented at the 81st Annual Scientific Sessions of the American Diabetes Association
    • 19 Apr 2021 Results published in the Diabetes Care

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top